Evidence map›Paper›PMID 39488509›Full record

ArticleScientific reports2024

Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches.

Liqing Jiang, Weifeng Huang, Mulan Cao, Yingsong Jiang, Simin Li, Mengling Li, Rui Yang, Zhongjun Wu, Yan Wang, Cheng Lv and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liqing Jiang *Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
Weifeng Huang *Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
Mulan Cao *Department of Oncology, Affiliated Hospital of Hebei University, Baoding City, Hebei, China.
Yingsong JiangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
Simin LiDepartment of Clinical Epidemiology and Center of Evidence-Based Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Mengling LiDepartment of Clinical Epidemiology and Center of Evidence-Based Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Rui YangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Zhongjun WuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
Yan WangGastroenterology Department, The Sixth People's Hospital of Shenyang, Shenyang, 110006, Liaoning, China. professor_wangyan@163.com.
Cheng LvCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, 110167, Liaoning, China. 1194062960@qq.com.
Zuotian HuangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China. 1351619201@qq.com.

Funding

Chongqing Research Performance Incentive and Guidance Project cstc2022jxjl120032Chongqing science and health joint project 2024GGXM005Chongqing technology innovation and application development key project cstc2021jscx-gksbX0060
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. This study investigates the role and mechanisms of ADAM9 as a biomarker and potential therapeutic target in HCC. Utilizing RNA-sequencing data and clinicopathological characteristics from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we conducted survival and meta-analyses, functional enrichment, and immune infiltration studies. Additionally, we evaluated the effects of ADAM9 silencing on HCC cell proliferation, migration, and invasion through in vitro experiments. Our results demonstrate that high ADAM9 expression is associated with poor prognosis and increased immune infiltration in HCC patients. Furthermore, ADAM9 knockdown significantly inhibited tumor cell proliferation and migration. These findings indicate that ADAM9 is a promising prognostic biomarker and potential therapeutic target in HCC. In conclusion, ADAM9 could offer avenues for developing strategies to inhibit tumor progression and improve patient outcomes.

Indexed as

ADAM ProteinsCarcinoma, HepatocellularLiver NeoplasmsMembrane ProteinsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationComputational BiologyGene Expression Regulation, NeoplasticHumansPrognosisADAM9 protein, humanADAM ProteinsBiomarkers, TumorMembrane ProteinsADAM9Bioinformatics analysisBiological functionsHCCPrognosis

Identifiers

PMID39488509
PMCPMC11531474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.